Key Highlights

● Evotec told the SEC that Dr. Cord Dohrmann will step down as Chief Scientific Officer effective September 30, 2026.

● He has held the role and a Management Board seat since 2010, a tenure of about 16 years.

● The press release says he is stepping down by mutual consent and that the company is searching for a successor.

● Evotec is a foreign private issuer, so the announcement came on Form 6-K and contains no separation agreement terms.

Evotec SE (NASDAQ:EVO) furnished a Form 6-K to the U.S. Securities and Exchange Commission on September 29, 2026, attaching a press release announcing that Dr. Cord Dohrmann will step down as Chief Scientific Officer effective September 30, 2026. The release, datelined Hamburg, Germany, says he has held the role and a seat on the Management Board since 2010, a tenure of about 16 years. It says the company is searching for a successor.

The Departure

The press release, titled "Evotec Announces Chief Scientific Officer Transition," says Dr. Dohrmann is stepping down by mutual consent. His last day in the role is September 30, 2026, the day after the filing. The release does not give a reason for the timing, and it does not describe any financial terms of his departure, any advisory or consulting arrangement, or whether he will remain associated with the company in another capacity.

The release does not name an interim Chief Scientific Officer and does not say who will oversee the scientific organization between his departure and the arrival of a successor. It says only that the search for a replacement is ongoing and gives no timeline for completing it.

Statements from the Company and from Dr. Dohrmann

Dr. Christian Wojczewski, Chief Executive Officer, is quoted as saying: "I would like to thank Cord for his long service and many contributions to Evotec over the past 16 years." He adds: "With his strategic vision for emerging technologies and future scientific trends, Cord has helped establish key capabilities across our platforms, including our iPSC-based technologies and omics capabilities." A further quote reads: "The robust science infrastructure that Cord has built will be an essential component of Evotec's future growth and profitability."

Dr. Dohrmann is quoted as saying: "The process of advancing new therapies from discovery to the clinic has evolved significantly over the past 16 years, and I have been privileged to contribute to that progress during my time at Evotec." He also says: "I am grateful for the support and collaboration of the many colleagues I have worked with in that time."

The release describes Evotec SE as a life science company that combines science with AI-driven innovation and advanced technologies across drug discovery and development. It lists services spanning small molecules, biologics and cell therapies, along with proprietary platforms that include Molecular Patient Databases, PanOmics and iPSC-based disease modeling. The company says it partners with Top 20 pharmaceutical companies and more than 800 biotechnology companies, employs approximately 4,500 people across European and U.S. sites, and focuses on oncology, cardiovascular and metabolic diseases, neurology and immunology. Those descriptions are the company's own.

About Evotec and the Filing Type

Evotec is a foreign private issuer, so it reports such announcements to the SEC on Form 6-K. Unlike a Form 8-K filed by a U.S. domestic company, a 6-K does not follow a fixed set of items, and this one consists of a short cover document and the press release. As a result, the filing does not include details such as the terms of any separation agreement, which a U.S. company might be required to describe under its officer-departure item.

Evotec's Search for a Chief Scientific Officer

The first date to note is September 30, 2026, when Dr. Dohrmann's departure takes effect. After that, the company's search for a new Chief Scientific Officer continues, and no timetable for completing it is given in the release.